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The inability of standard therapy to provide adequate protection against poisoning by organophosphorus compounds 
(pesticides and nerve agents) motivated us to search for new, more effective oximes. We investigated the 
pharmacotoxicological properties of six experimental K-oximes (K027, K033, K048, K074, K075, and K203) in vivo. 
The therapeutic efficacy of K-oximes (at doses of 5 or 25 % of their LD50) combined with atropine was assessed in 
paraoxon-poisoned mice and compared with conventionally used oximes HI-6 and TMB-4. The bisoxime K074 was the 
most toxic (LD50=21.4 mg kg
-1) to mice, while monoxime K027 was the least toxic (LD50=672.8 mg kg
-1). With the 
exception of K033, all of the tested K-oximes showed better therapeutic efficiency than HI-6 and TMB-4. K027 and K048 
stood out by demonstrating low acute toxicities and ensuring protective indices ranging from 60.0 to 100.0 LD50 of 
paraoxon. Taking into account that these two oximes showed a similar therapeutic efficacy regardless of the applied doses, 
our results suggest that K027 and K048 could be antidotes for paraoxon intoxication.
KEY WORDS: acute toxicity; mice; therapeutic efficacy
Žunec S, et al. Comparative determination of the efficacy of bispyridinium oximes in paraoxon poisoning 
Arh Hig Rada Toksikol 2015;66:129-134
Organophosphorus (OP) compounds are a heterogeneous 
group of organic compounds that represent a serious 
toxicological problem and therapeutic challenge (1). The 
introduction of synthetic OP compounds half a century ago 
has resulted in the repeated misuse of nerve agents during 
military conflicts and terrorist attacks as well as 3 million 
cases of poisoning by pesticides, all leading to nearly 
260,000 human fatalities per year (2-4). The main toxic 
mechanism of OP compounds involves the inhibition of 
esterase enzymes; acetylcholinesterase (AChE) in synapses 
and red blood cell membranes, and butyrylcholinesterase 
(BChE) in plasma (5). Although acute BChE inhibition does 
not seem to cause clinical manifestations, AChE inhibition 
results in the accumulation of the neurotransmitter 
acetylcholine (ACh) at cholinergic synapses, with an 
overstimulation of cholinergic receptors of the muscarinic 
and nicotinic type (5). As these receptors are localised in 
most organs, a “cholinergic syndrome” may ensue increased 
sweating and salivation, profound bronchial secretion, 
bronchoconstriction, miosis, increased gastrointestinal 
motility, diarrhoea, tremors, muscular twitching, and 
various negative effects on the central nervous system. 
Death is believed to be due to respiratory failure (5).
Standard post-exposure antidotal treatment of OP 
poisoning includes administrating an anticholinergic drug 
such as atropine and AChE reactivators called oximes in 
accordance with the functional oxime group. Atropine 
decreases the effects of excess ACh primarily by blocking 
peripheral muscarinic receptor sites, resulting in reduced 
secretion and reversing the constriction of smooth muscles. 
Since it has little effect on nicotinic sites, skeletal muscle 
fasciculation continues, resulting in the paralysis of 
respiratory muscles, i.e., peripheral respiratory failure (6). 
Oximes break the OP-AChE bond and restore the activity 
of inhibited AChE (7). Thus far, only four oximes of a 
pyridinium aldoxime structure (2-PAM, TMB-4, HI-6, and 
obidoxime) have found clinical application, but none is 
sufficiently effective against all of the known OP 
compounds (7). Due to this fact, laboratories worldwide 
are searching for a broad spectrum AChE reactivator. 
K-oximes appear to be among the most promising 
compounds developed (8-10). 
Therefore, the present study was undertaken to assess 
and compare the therapeutic efficacy of six experimental 
K-oximes (K027, K033, K048, K074, K075, and K203) 




K-series oximes K027, K033, K048, K074, K075 and 
K203 were prepared as described earlier (11-15). TMB-4 
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[1,3-bis(4-hydroxyiminomethylpyridinium) propane 
dichloride] was synthesised in Bosnalijek, Sarajevo, Bosnia 
and Herzegovina, while HI-6 [(1-(2- hydroxyiminomethyl-
pyridinium)-3-(4-carbamoylpyridinium)-2-oxapropane 
dichloride)] was synthesised at the University of Defence, 
Hradec Kralove, Czech Republic (16). Oximes were kept 
at room temperature and dissolved in distilled water or 
atropine immediately before use. Paraoxon (diethyl 
p-nitrophenyl phosphate) was purchased from Sigma-
Aldrich, Steinheim, Germany. The stock solution of 
50 mg mL-1 of paraoxon was prepared in isopropanol. 
Further dilutions were made in saline, shortly before use. 
Atropine sulphate was purchased from Kemika, Zagreb, 
Croatia. The solution of 5 mg mL-1 of atropine was prepared 
in distilled water.
Animals
Male NIH/Ola Hsd mice were purchased from the 
Institute of Immunology, Inc., Department of Experimental 
Animals and Antisera, Zagreb, Croatia. The mice were kept 
in Macrolone cages at 21 °C maintained by a thermostat 
with exchanging light and dark cycles every 12 h. The 
animals were fed a standard diet (4RF21, Mucedola, 
Milano, Italy) with free access to water. Selection was made 
by body weight (18-25 g) following random distribution 
into groups of four animals. This study was performed with 
the approval of the Ethics Committee of the Institute for 
Medical Research and Occupational Health in Zagreb, 
Croatia.
Acute toxicity 
Acute toxicity (LD50) was based upon 24 h-mortality 
rates calculated according to Thompson and Weil (17-18). 
Each LD50 was evaluated from the results obtained with 
four to six doses of a given compound and four animals 
were injected per dose. Whenever the results of the 
experiment allowed, the 95 % confidence limits were 
estimated from tables described elsewhere (17-18).
Therapeutic efficacy
The therapeutic effect against paraoxon poisoning was 
tested by administering the studied oximes (5 or 25 % of 
their LD50) together with atropine sulphate (10 mg kg
-1), 
immediately after paraoxon. The OP compound was given 
subcutaneously (s.c.) while therapy was administered 
intraperitoneally (i.p.). Mice were observed for 24 h and 
the antidotal efficacy of the tested oximes was expressed 
as protective index (PI) and maximal dose of poison (MDP). 
PI was the ratio of LD50 between OP with antidote and OP 
given alone. MDP was the highest multiple of the LD50 of 
OP, which was fully counteracted (survival of all animals) 
by the antidote.
RESULTS AND DISCUSSION
The inadequacy of standard therapy to provide 
protection against OP poisoning is a matter of continuous 
public and scientific concern. Within the last few years, a 
new generation of oximes has been developed in the Czech 
Republic (8). Structurally, they are bispyridinium oximes 
that differ in the length of the connection chain between 
two pyridinium rings, the position of the oxime group, and 
the number of oxime groups in a molecule. Promising 
results using several of the previously mentioned oximes 
were obtained for poisoning by the nerve agent tabun, as 
well as in the case of pesticide poisoning (8, 14, 19-29). 
Although the use of OP pesticides is under restriction in 
most parts of the world, especially in developed countries, 
some, such as parathion, are still widely (mis)used (30). 
The active metabolite of the insecticide parathion, paraoxon, 
is one of the most potent acetylcholinesterase-inhibiting 
compounds available (30). Therefore, it is important to 
determine the antidotal potency of new oximes in paraoxon 
poisoning. Previous studies have shown good potency of 
several K-oximes in vitro to reactivate AChE inhibited by 
paraoxon (22-23, 25, 27, 29). In the present study, we used 
mice as an experimental model to broaden our knowledge 
on the pharmacotoxicological properties of six K-oximes 
(K027, K033, K048, K074, K075, and K203). The 
conventional oximes HI-6 and TMB-4 were included for 
comparison.
The acute toxicity (LD50; i.p.) of the tested oximes is 
shown in Table 1. Bisoximes K033, K074, and K075 were 
more toxic than monoximes K027 and K048, which is not 
surprising considering that oximes with two oxime groups 
have a higher affinity for native AChE (31). For example, 
bisoxime TMB-4 is the most toxic of the four mentioned 
conventional oximes (7) and the novel oximes K027 and 
K048 had nearly an eight and three-times lower acute 
toxicity, respectively, than TMB-4. Moreover, with an LD50 
of 672.8 mg kg-1 body weight, K027 was the least toxic. 
Our result agrees with in vitro studies performed by 
Petroianu and Lorke (26) and Lorke et al. (32), which 
singled out K027 as the least toxic in comparison with the 
other oximes tested. An exception was noticed in the case 
of monoxime K203. Although K203 has one oxime and one 
carbamoyl moiety just like K027 and K048, its different 
stereoelectronic profile is probably why its LD50 was so low 
(33). 
Tables 2 and 3 show the therapeutic effects of the tested 
oximes combined with atropine on paraoxon toxicity in 
male mice. Exposure to paraoxon led to classical signs of 
cholinergic toxicity, but severe signs of toxicity were also 
observed in all of the animals despite antidotal treatment. 
Muscle fasciculation and tremor generally occurred within 
1-2 min after poisoning. Convulsions appeared with a 
latency of 3-4 min. During the acute phase, all of the animals 
exhibited dyspnoea and cyanosis. The animals that survived 
remained active for 24 h. 
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Table 1 Chemical name, structure, and LD50 of the tested oximes in male mice
Compound Code Structure
LD50 (mg kg-1)
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The administration of a single atropine dose of 
10 mg kg-1 one minute after paraoxon resulted in a protective 
index (PI) of 5.9, although in most cases of nerve agent 
poisoning, therapy with atropine alone results in a PI below 
2 (34). Even though it seemed that atropine reduced the 
signs of cholinergic toxicity elicited by paraoxon more 
efficiently than that caused by nerve agents, survival was 
improved and symptoms reduced only following the 
coadministration of oximes. A marked improvement in the 
therapy of paraoxon poisoning was noticed with all of the 
tested oximes compared to atropine alone (Tables 2 and 3). 
When they were applied at a dose of 5 % of their LD50, 
conventional oximes HI-6 and TMB-4 ensured a PI of 20.0. 
The PI of the equitoxic dose of K-oximes ranged from 15.9 
to 100.0 LD50 of paraoxon (Table 2). The best results were 
obtained with oximes K027 and K048. The PI of the therapy 
composed of K027 or K048 and atropine was about 15 times 
better than that obtained by atropine alone. Moreover, these 
combinations ensured the survival of all animals at up to 
63.0 LD50 of paraoxon. A dose-response relationship was 
observed for K074, K075, and K203, as an increase of the 
therapeutic dose from 5 to 25 % of their LD50 resulted in a 
2 to 5 times higher PI (max. was 171.5). The highest PI was 
obtained using 25 % of K075 and K203 LD50 together with 
atropine, where all animals survived up to 100.0 LD50 of 
paraoxon (Table 3). These results confirmed the hypothesis 
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Table 2 Therapeutic effect of the tested oximes (5 % of their LD50) combined with atropine upon (s.c.) paraoxon toxicity* in male mice
Treatment LD50 (μg kg-1)
95 % confidence limits 
(μg kg-1) PI MDP
atropine 4191.8 3563.3-4931.2 5.9 5.0
K027 + atropine 64032.4 50321.0-81479.8 74.1 50.4
K033 + atropine 13721.4 10356.2-18180.3 15.9 12.6
K048 + atropine 86457.0 56689.2-131856.0 100.0 63.0
K074 + atropine 23528.8 18491.0-29939.2 27.2 20.0
K075 + atropine 29648.3 23302.4-37722.5 34.3 25.2
K203 + atropine 24451.2 16966.8-35237.1 28.3 15.8
HI-6 + atropine 17290.2 8991.5-33248.3 20.0 12.6
TMB-4 + atropine 14282.4 10936.3-18652.2 20.0 20.0
*LD50 (paraoxon)=864.3 μg kg-1
PI-protective index
MDP–maximal dose of poison
Table 3 Therapeutic effect of the tested oximes (25 % of their LD50) combined with atropine upon (s.c.) paraoxon toxicity* in male mice
Treatment LD50 (μg kg-1)
95 % confidence limits 
(μg kg-1) PI MDP
atropine 4191.8 3563.3-4931.2 5.9 5.0
K027 + atropine 54992.1 44222.2-68384.9 63.6 50.4
K033 + atropine 21782.1 14282.4-33220.0 25.2 15.8
K048 + atropine 51903.4 43503.0-61927.0 60.0 40.0
K074 + atropine 47141.1 37051.0-59979.1 54.5 40.0
K075 + atropine 148217.1 116493.0-188582.0 171.5 100.0
K203 + atropine 108918.1 82205.3-144311.2 126 63.0
HI-6 + atropine 20594.4 17261.2-24571.4 23.8 15.9
TMB-4 + atropine 28523.3 21527.8-37792.0 40.0 25.2
*LD50 (paraoxon)=864.3 μg kg-1
PI-protective index
MDP–maximal dose of poison
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that oxime reactivation is a very important treatment 
modality for OP compound poisoning. 
Oximes exhibit their potency by enabling the recovery 
of an active AChE in contrast to the symptomatic treatment 
of excessive cholinergic stimulation with atropine largely 
in the periphery. By testing the therapeutic efficacy of newer 
oximes in paraoxon-poisoned mice, we aimed to single out 
compound(s) that would be more effective than the oximes 
used currently. With the exception of K033, all of the oximes 
showed better antidotal activity than HI-6 and TMB-4. 
Unfortunately, the high acute toxicity of these oximes is a 
limiting factor for their usage. The protective index of the 
two less toxic oximes, K027 and K048, ranged from 60.0 
to 100.0. Moreover, therapy with both 5 and 25 % LD50 
doses of K027 plus atropine resulted in the survival of all 
animals at a 50.4 LD50 dose of paraoxon. A similar result 
was obtained for K048, with the exception that a higher 
therapeutic efficiency was achieved with a lower dose of 
this oxime (5 % of the respective LD50). Results of our in 
vivo experiments on mice showed a relatively good 
correlation with in vitro results obtained by other authors. 
To be more precise, oximes K027 and K048 were found to 
be potent reactivators of the erythrocyte AChE in in vitro 
studies with methyl-, ethyl-paraoxon and DFP (23, 25-27, 
29). Thus, it seems that these compounds have a 
pharmacological effect indeed related to the reactivation of 
paraoxon-inhibited AChE, and - what is even more 
important - these oximes can be used at lower doses, 
applicable for human use. 
In summary, this study indicates a higher potency of 
the majority of the tested K-oximes to protect against high 
lethal doses of paraoxon when compared to the conventional 
oximes HI-6 and TMB-4. Among the tested oximes, K027 
and K048 stood out with low acute toxicities and very good 
antidotal effects. We can conclude that K027 and K048 
might be antidotes for paraoxon intoxication therapy.
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Usporedno određivanje učinkovitosti bispiridinijevih oksima pri trovanju paraoksonom
Činjenica da standardna terapija ne omogućuje dovoljnu zaštitu pri otrovanju organofosfornim spojevima (pesticidima i 
živčanim bojnim otrovima) potaknula nas je na istraživanje novih, učinkovitijih oksima. U uvjetima in vivo ispitali smo 
farmakotoksikološka svojstva šest eksperimentalnih K-oksima (K027, K033, K048, K074, K075 i K203). Terapijski učinak 
kombinacije K-oksima (primjenjenih u dozi 5 ili 25 % njihove LD50) i atropina testiran je na miševima otrovanim paraoksonom 
i uspoređen s konvencionalnim oksimima HI-6 i TMB-4. Bisoksim K074 je bio najtoksičniji (LD50=21.4 mg kg
-1) za miševe, 
dok je monooksim K027 bio najmanje toksičan (LD50=672.8 mg kg
-1). Osim K033, svi K-oksimi pokazali su bolji terapijski 
učinak u miševa trovanih paraoksonom u odnosu na HI-6 i TMB-4. Iz skupine testiranih oksima istaknuli su se K027 i 
K048 koji su pokazali nisku akutnu toksičnost i osigurali protektivne indekse u rasponu od 60.0 do 100.0 LD50 paraoksona. 
Uzmemo li u obzir da su ta dva oksima pokazala sličan terapijski učinak bez obzira na primjenjenu dozu, prikazani rezultati 
upućuju na K027 i K048 kao perspektivne antidote u terapiji trovanja paraoksonom. 
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